Skip to main content
Article
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Journal of Clinical Oncology (1996)
  • Barry L. Gause, National Institutes of Health
  • Mario Sznol, National Institutes of Health
  • William C. Kopp, National Institutes of Health
  • John E. Janik, National Institutes of Health
  • John W. Smith, National Institutes of Health
  • Ronald G. Steis, National Institutes of Health
  • Walter J. Urba, National Institutes of Health
  • William Sharfman, National Institutes of Health
  • Robert G. Fenton, National Institutes of Health
  • Steven P. Creekmore, National Institutes of Health
  • Jon Holmlund, National Institutes of Health
  • Kevin C. Conlon, National Institutes of Health
  • Louis A. VanderMolen, National Institutes of Health
  • Dan L. Longo, National Institutes of Health
Publication Date
January 8, 1996
DOI
10.1200/JCO.1996.14.8.2234
Citation Information
Barry L. Gause, Mario Sznol, William C. Kopp, John E. Janik, et al.. "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer." Journal of Clinical Oncology Vol. 14 Iss. 8 (1996) p. 2234 - 2241
Available at: http://works.bepress.com/walter-urba/26/